Participated · Series D · Aug 2026

Abcuro develops immunotherapies intended to benefit people with debilitating and progressive rare autoimmune diseases by selectively targeting and depleting highly cytotoxic T cells. Its lead program, ulviprubart, is a monoclonal antibody that targets killer cell lectin like receptor G1 (KLRG1) and is currently being evaluated for the treatment of Inclusion Body Myositis (IBM). The company plans to use proceeds from the Series D to support a new potentially registrational clinical study of ulviprubart in patients with less severe IBM. Abcuro is led by CEO Alex Martin and is based in Newton, MA. Financially, it has just completed a $66M Series D financing led by New Leaf Venture Partners with participation from a broad syndicate of life sciences and strategic investors.

Led · Series B · Jul 2026

Claris Biotherapeutics, spun out of the Harvard lab of corneal disease expert Reza Dana, is developing CSB-001 (oremepermin alfa), an eye drop candidate now targeted at limbal stem cell deficiency (LSCD) after an initial neurotrophic keratitis study failed but showed benefit in LSCD patients. The company plans a phase 3 pivotal trial of CSB-001 beginning in the first half of 2027 with a data readout expected within roughly two years. Claris is running a non-interventional natural history study to better understand LSCD and to create a pool of subjects for its phase 3 trial. The biotech has grown from an initial team of five to more than 25 employees and is seeking to establish a physical headquarters. CEO Stephen Brady, who took over June 15, said the company intends to educate providers on diagnosing LSCD and expects to explore additional indications or pipeline expansion if independent and capitalized. Brady also anticipates taking the company public before phase 3 readout, either via IPO or a reverse merger.

Participated · Series B · Jun 2026

Nura Bio is a clinical-stage biopharmaceutical company focused on developing small molecule neuroprotective therapies that halt axon degeneration by inhibiting SARM1. Its lead programs include NB-4746, a first-generation oral, brain-penetrant reversible orthosteric SARM1 inhibitor currently in a Phase 1b/2a global ALS study, and NB-9402, a second-generation oral covalent irreversible allosteric SARM1 inhibitor in a Phase 1a first-in-human study. NB-4746 demonstrated a favorable safety profile and achieved target plasma and cerebrospinal fluid exposure in a Phase 1 study in healthy volunteers, and preclinical studies支持 neuroprotection across central, peripheral, and ocular nervous system models. The company intends to use proceeds from its recently completed $73.8M Series B to fund clinical proof-of-biology studies and advance its clinical pipeline. Nura Bio is based in South San Francisco and is positioning a portfolio of differentiated SARM1 inhibitors to explore therapeutic potential across multiple neurological diseases.

Participated · Series A · Apr 2026

Coultreon Biopharma focuses on developing therapies that target clinically validated pathways in immunology and metabolic diseases, leveraging expertise in disease biology, drug discovery and translational science. Its pipeline centers on selectively modulating salt-inducible kinase (SIK) biology to address key inflammatory pathways. The company's lead program, COL-5671 (formerly O3R-5671), is a highly selective, oral once-daily SIK3 inhibitor currently in Phase 1 clinical studies. Coultreon intends to use the $125M Series A proceeds to support further clinical development of COL-5671. The company is led by CEO Pierre Raboisson and is based in Leuven, Belgium. No revenue, user, founding year or prior-round financial metrics were reported in the article.

Participated · Series B · Apr 2026

Sidewinder Therapeutics is focused on engineering next-generation bispecific ADCs that target tumor-specific receptor co-complexes to enhance tumor specificity and internalization. The company’s pipeline targets indications including squamous cell carcinomas of the lung and head and neck and gastrointestinal cancers such as colorectal cancer. Sidewinder was founded in 2023 and is headquartered in San Diego. It has partnered with Lonza to apply Synaffix’s site-specific linker‑payload platform across multiple programs. The company plans to advance its lead program into clinical development in 2027. Financially, Sidewinder has raised a total of $162 million following the $137 million Series B.